SI-BONE's innovative approach fuels both EBITDA gains and increased revenue
- SI-BONE reported Q3 2025 adjusted EBITDA of $2. 3M and raised full-year revenue guidance to $198M–$200M. - Gross margin expanded to 79.8%, while operating losses narrowed by 29.5% despite 11.9% higher operating expenses. - Cash reserves remained stable at $145.7M, with CEO citing growth from minimally invasive solutions and global expansion. - Analysts highlight innovation and expanded indications as key drivers for future orthopedic market share gains.
On November 10, 2025, SI-BONE, Inc. (NASDAQ: SIBN) announced its third-quarter 2025 financial results, surpassing expectations with a positive adjusted EBITDA and an updated annual revenue outlook now ranging from $198 million to $200 million. The company, recognized worldwide for its sacropelvic disorder solutions, also revealed plans for a conference call to provide a detailed review of its latest performance.
Gross margin improved to 79.8% in the third quarter of 2025, an increase of 75 basis points from 79.1% in the same quarter last year, attributed to enhanced operational efficiency. Operating expenses climbed by 11.9% to $44.2 million, reflecting expanded commercial efforts for new product introductions and higher administrative spending. Despite these increases, the operating loss was reduced by 29.5% to $5.4 million, and net loss narrowed by 30.6% to $4.6 million, or $0.11 per diluted share, compared to $6.6 million, or $0.16 per share, a year earlier.
As of September 30, 2025, SI-BONE’s cash balance stood at $145.7 million, unchanged from the prior quarter. The company raised its full-year 2025 outlook, now expecting revenue to grow by 18-20% to between $198 million and $200 million, while maintaining a gross margin near 79.5%. These projections highlight the company’s confidence in its market standing, with CEO David B. Robinson crediting the results to “the ongoing adoption of our minimally invasive solutions” and the company’s expanding international presence.
The updated outlook demonstrates SI-BONE’s ability to thrive in a challenging healthcare environment. Since introducing minimally invasive sacroiliac joint procedures in 2009, the company has enabled more than 4,900 physicians to perform over 135,000 surgeries. Industry analysts point out that SI-BONE’s emphasis on innovation and broadening the use of its technologies positions it well to further increase its share in the orthopedic market.
A live webcast and conference call to review the financial results will take place on November 10, 2025, at 4:30 p.m. Eastern Time. The event will be accessible for at least 90 days afterward, with live audio streaming available on SI-BONE’s investor relations website.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin News Update: Bitcoin's Dominance Wanes as Institutional Investors Turn to Altcoins Amid Changing Market Trends
- Bitcoin's market dominance fell to 59.90% in November, signaling potential capital rotation to altcoins as analysts debate an emerging altcoin season. - Mixed signals from the Altcoin Season Index (100 vs. 28) reflect fragmented sentiment, with Solana and XRP attracting $146M in institutional inflows amid Bitcoin outflows. - Technical indicators suggest a "dead cat bounce" in Bitcoin dominance, with historical parallels to 2019-2020 cycles hinting at prolonged altcoin-friendly conditions. - JPMorgan fore
Bitcoin Updates: MicroStrategy’s Bold Bitcoin Bet: mNAV Drops Under 1, Raising Concerns Over Possible Liquidation
- MicroStrategy CEO Saylor dismissed Bitcoin sale rumors after a $5.7B wallet transfer, reaffirming the company's commitment to buying more crypto amid market volatility. - The mNAV ratio dipping below 1 triggered fears of a "death spiral," as MicroStrategy's market cap now lags behind its Bitcoin holdings, raising leverage risks. - Competitors like BSTR and Reitar Logtech are expanding Bitcoin treasuries, reflecting growing institutional interest despite market uncertainty. - Critics warn of forced liquid
"Global financial markets caught in a struggle as the Federal Reserve weighs concerns over inflation against the need for liquidity"
- Fed officials' divided views on rate cuts triggered global market declines, with Asian and European indices falling amid inflation concerns. - UK unemployment rose to 5.0% while Switzerland secured a 15% US tariff cut, boosting growth projections and bilateral investments. - Data gaps before the Fed's December meeting intensified uncertainty, with investors pricing in shifting cut probabilities and hoarding $7.535T in cash. - Central banks face balancing acts as 10-year Treasury yields climbed to 4.125%,
Solana News Update: Institutions Invest $370 Million in Solana ETFs Amid 5-Month Price Slump
- Solana ETFs (BSOL/GSOL) gained $370M in inflows despite SOL hitting 5-month lows amid broader crypto declines. - Contrasts Bitcoin/ETH ETF outflows ($870M BTC exodus) as institutional demand for Solana remains strong. - Technical indicators signal potential $100 support break, but ETF inflows persist with NYSE options boosting participation. - Market divides: $150 resistance vs. $142 support levels, with RSI near oversold but bullish divergence emerging.
